$LFWD

Lifeward Ltd. (LFWD) published a study on long-term use of its ReWalk Personal Exoskeleton, showing positive results in seven individuals with chronic paraplegia. The study, conducted by Andrea Giovanni Cutti and colleagues, reported no falls or fractures, with participants walking a median distance of 129 meters in a six-minute test. The exoskeleton is FDA-cleared and CE Marked, covered by Medicare for eligible beneficiaries.

Lifeward's CFO nominee, Rami Aviram, declined the position. Josh Hexter will continue as interim CFO. The company is searching for a permanent replacement.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in Current Reports on Form 8-K filed with the Securities and Exchange Commission on August 31, 2026

Lifeward Ltd. (LFWD) named Josh Hexter as interim CFO effective October 1, 2026, following Almog Adar's departure. Hexter will serve until Rami Aviram's appointment on November 1, 2026. According to the company, Hexter also serves as interim CEO and will not receive additional compensation for the interim CFO role.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Current Report on Form 8-K filed by Lifeward Ltd. (the “Company”) with the Securities and Ex

Lifeward Ltd. (LFWD) published a study showing its ReWalk exoskeleton improves daily activities, satisfaction, and reduces pain for spinal cord injury patients. All 12 participants performed kitchen activities, 10 did grooming. ReWalk sales rose 13% YoY to $2.5M in Q2 2026, with total LFWD revenue up 16% to $6.6M. LFWD stock is currently at $7.11, down 0.14%.

Oramed Pharmaceuticals (ORMP) has entered a milestone-based funding deal with Lifeward (LFWD), a maker of exoskeleton devices. Lifeward highlighted its strategic partnership with Oramed in an investor presentation, noting potential benefits and funding availability. The company aims to leverage robotics, AI, and reimbursement to grow in the rehabilitation market, with projections of significant market expansion by 2030.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NASDAQ: LFWD Platform to Restore Motion, Dignity, and Independence Transforming Rehabilitation. Changing Lives. Investor Presentation · September 2026 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of Section 2

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of President and Chief Executive Officer Effective August 31, 2026, Mr. Mark Grant will depart from his positions

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. Appointment of Directors On August 14, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) appointed